Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls

Annals of Neurology

Volumn 73, Issue 1, 2013, Pages 104-119

  Esparza, Thomas J ^a   Zhao, Hanzhi ^a   Cirrito, John R ^a   Cairns, Nigel J ^a   Bateman, Randall J ^a   Holtzman, David M ^a   Brody, David L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL LYSATE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; NEUROPATHOLOGY; OLIGOMERIZATION; PHOTON; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ASSAY; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; PROTEIN MULTIMERIZATION;

EID: 84873328025     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23748     Document Type: Article

References (54)

1. Price JL, Morris JC,. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
2. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
3. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57: 1168-1174.
4. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988; 23: 138-144.
5. Selkoe DJ,. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-113.
6. Wang HW, Pasternak JF, Kuo H, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002; 924: 133-140.
7. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998; 95: 6448-6453.
8. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-489.
9. Dahlgren KN, Manelli AM, Stine WB Jr, et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053.
10. Ono K, Condron MM, Teplow DB,. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 2009; 106: 14745-14750.
11. Townsend M, Shankar GM, Mehta T, et al. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006; 572 (pt 2): 477-492.
12. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-539.
13. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
14. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79-84.
15. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
16. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077-4081.
17. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003; 100: 10417-10422.
18. Tomic JL, Pensalfini A, Head E, Glabe CG,. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009; 35: 352-358.
19. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
20. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 2005; 102: 2273-2276.
21. Englund H, Sehlin D, Johansson AS, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem 2007; 103: 334-345.
22. Hillen H, Barghorn S, Striebinger A, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 2010; 30: 10369-10379.
23. Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006; 281: 4292-4299.
24. Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007; 100: 23-35.
25. Lambert MP, Viola KL, Chromy BA, et al. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001; 79: 595-605.
26. van Helmond Z, Heesom K, Love S,. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J Neurosci Methods 2009; 176: 206-212.
27. Howlett D, Cutler P, Heales S, Camilleri P,. Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Lett 1997; 417: 249-251.
28. Sian AK, Frears ER, El-Agnaf OM, et al. Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types. Biochem J 2000; 349 (pt 1): 299-308.
29. LeVine H III,. Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 2004; 335: 81-90.
30. Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009; 66: 190-199.
31. Klaver AC, Patrias LM, Finke JM, Loeffler DA,. Specificity and sensitivity of the Abeta oligomer ELISA. J Neurosci Methods 2011; 195: 249-254.
32. DeMattos RB, O'Dell MA, Parsadanian M, et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2002; 99: 10843-10848.
33. Todd J, Freese B, Lu A, et al. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem 2007; 53: 1990-1995.
34. Schwetye KE, Cirrito JR, Esparza TJ, et al. Traumatic brain injury reduces soluble extracellular amyloid-beta in mice: a methodologically novel combined microdialysis-controlled cortical impact study. Neurobiol Dis 2010; 40: 555-564.
35. Giraldo J, Vivas NM, Vila E, Badia A,. Assessing the (a)symmetry of concentration-effect curves: empirical versus mechanistic models. Pharmacol Ther 2002; 95: 21-45.
36. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003; 20: 1885-1900.
37. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
38. Kim J, Castellano JM, Jiang H, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009; 64: 632-644.
39. Styren SD, Hamilton RL, Styren GC, Klunk WE,. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000; 48: 1223-1232.
40. Fagan A, Younkin L, Morris J, et al. Differences in the Ab40/Ab42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000; 48: 201-210.
41. Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
42. Tran HT, Sanchez L, Esparza TJ, Brody DL,. Distinct temporal and anatomical distributions of amyloid-β and tau abnormalities following controlled cortical impact in transgenic mice. PloS One 2011; 6: e25475.
43. Kim K, Wen G, Bancher C, et al. Detection and quantitation of amyloid b-peptide with 2 monoclonal antibodies. Neurosci Res Commun 1990; 7: 113-122.
44. Ramakrishna N, Saikumar P, Potempska A, et al. Expression of human Alzheimer amyloid precursor protein in insect cells. Biochem Biophys Res Commun 1991; 174: 983-989.
45. DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98: 8850-8855.
46. Horikoshi Y, Sakaguchi G, Becker AG, et al. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun 2004; 319: 733-737.
47. Holton JL, Lashley T, Ghiso J, et al. Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol 2002; 61: 254-267.
48. Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999; 399: 776-781.
49. Saido TC, Iwatsubo T, Mann DM, et al. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995; 14: 457-466.
50. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30: 1026-1036.
51. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 2011; 108: 5819-5824.
52. Fukumoto H, Tokuda T, Kasai T, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 2010; 24: 2716-2726.
53. Klyubin I, Betts V, Welzel AT, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 2008; 28: 4231-4237.
54. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 2009; 106: 4012-4017.